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Purpose: There are few studies about clinical courses following acute bacterial prostatitis (ABP). We evaluated the progression rates 
of chronic bacterial prostatitis (CBP) and inflammatory chronic pelvic pain syndrome (CPPS) after ABP treatment. Also evaluated the 
characteristics of the patients who developed CBP and inflammatory CPPS after ABP treatment.
Methods: Total 437 patients compatible with a confirmed diagnosis of ABP from 5 urological centers between 2001 and 2010 were 
enrolled to study. We defined chronic infection (CI) as a progression to CBP and inflammatory CPPS after treatment of ABP in admission 
periods when followed up at 3 months or more. Results were analyzed between two groups: recovered without CI (group A, n=385) 
and developed to CI (group B, n=52). 
Results: Of the 437 ABP patients, 1.3% (6/437) progressed to CBP and 10.5% (46/437) progressed to inflammatory CPPS. The progression 
rate of CI was 11.8% (52/437). The patients who developed to CI were higher in alcohol consumption rate, diabetes, voiding symptoms, 
prior manipulation rate, enlarged prostate volume, catheterization history rate and short duration of antibiotic treatment (P<0.05). 
Conclusions: The identification and characterization of these factors may accelerate the development of preventive, diagnostic and 
therapeutic strategies for the treatment of CI from ABP.
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INTRODUCTION
Acute bacterial prostatitis (ABP) is an uncommon disease that 
takes only about 5% of prostatitis [1]. ABP is acute inflamma-
tion inside the prostate tissues, presenting similar symptoms 
to lower urinary tract infections (UTIs) of women in terms 
of causal bacteria and urinary virulence factors but its host 
response is very different from uncomplicated cystitis and its 
treatment process is more complex [2]. Common symptoms 
of ABP include fever, chill, rectal pain, lower back pain, peri-
neal pain and increased urinary frequency and urgency as 
well as painful urination [3]. In severe case, the patient can 
show symptoms related to sepsis such as high fever, chills, 
cardiovascular instability and change of consciousness. The 
initial treatment of ABP is to administer high dose antibiot-
ics intraveonousely until symptoms and signs such as fever, 
infection and others are resolved. After symptoms improved, 
the medication should be changed into oral antibiotics such 
as fluoroquinolone and administer it for 4 weeks at least [4].
 Recently, with advancement of treatment with antibiotics, 
most patients with ABP recover without having complica-
tions. In most studies, clinical pattern, progression and risk 
factors of prostatitis focus on chronic bacterial prostatitis 
(CBP) rather than ABP. The progression rate of acute ABP to 
CBP has been reported as between 4.2% to 8.1% [5,6]. How-
ever, there is no report on the progression rate from ABP to 
CBP and inflammatory chronic pelvic pain syndrome (CPPS). 
The authors defined chronic infection (CI) as post-treatment 
progression of ABP to CBP as well as inflammatory CPPS, and 
examined the progression rate to CBP as well as inflammatory 




CPPS were confirmed by the prostate massage test (Meares-
Stamey four glass test).
 Patients were divided into two groups; recovered without 
progression to CI (group A, n=385) and the group with pro-
gression to CI (group B, n=52). We evaluated the progression 
rate CI from ABP and also evaluated the clinical and micro-
biological characteristics of the patients in both groups. 
 We defined the alcohol intake as patients who drinks al-
cohol once or more per month and smoking history as who 
smoked at the time of diagnosis regardless the number of ciga-
rettes. Patients who takes medications at the time to diagnose 
ABP were defined as diabetes and hypertension. The body 
temperature >37.5°C was defined as fever, visual pain score 
>6 was defined as pain, and residual urine volume exceeding 
300 mL was defined as urinary retention. When the sums of 
voiding symptoms and storage symptoms were 7 points and 5 
points respectively in accordance with the International Pros-
tate Symptom Score, they were defined as voiding symptoms 
and storage symptoms. Those patients undergone prostate 
biopsy, Foley catheterization, urodynamic study and transure-
thral ressetion of prostate within 4 weeks prior to onset of ABP 
were defined as prior manipulations. 
 Results (frequency and percentages) were analyzed to char-
acterize all variables using Student t test, the χ2 tests, and mul-
tiple logistic regression analysis. Numereical data given in our 
data were standard deviation. P-value <0.05 was considered 
CPPS from ABP and the characteristics of the CI patients after 
ABP treatment. 
MATERIALS AND METHODS
This study was conducted in 625 patients who were diagnosed 
with ABP and had been treated as in-patients at 5 hospitals 
from March of 2001 to October 2010 as a retrospective analy-
sis. The patients who were diagnosed with prostate cancer at 
the time of hospitalization or during the follow-up study pe-
riod for 24 months in average after being diagnosed with the 
infection had been excluded from this study. All patients had 
been diagnosed as ABP according to the clinical symptoms 
(fever, dysuria, painful prostate on digital rectal examination) 
and the laboratory findings. Those patients with symptoms of 
ABP and showing positive urine culture, but also those who 
had shown negative response to urine culture test due to the 
use of antibiotics but presented typical symptoms of ABP were 
diagnosed as ABP. When the diagnosis of ABP was not clear, 
those patients were excluded and so were those who had fe-
ver unrelated to UTI or who were unable to trace for follow-up 
study during treatment period. Finally, 437 patients who were 
suitable for diagnosis of ABP were included in this study. 
 The authors defined the case that had progressed to CBP 
and inflammatory CPPS after treatment follow-up of ABP 
over 3 months as CI. Diagnoses of CBP and inflammatory 
Table 1. Clinical characteristics of acute bacterial prostatitis patients
Characteristic Total (n=437) Group A (n=385) Group B (n=52) P-value
Age (yr)    56.4±13.2    56.0±14.7    56.8±12.5 0.71
Body mass index (kg/m2) 23.7±4.0 23.7±3.0 24.1±2.9 0.187
Alcohol 38.9 38.5 40.4 <0.05
Smoking 36.3 36.1 36.5 0.712
STI history 16.9 15.6 17.3 0.749
Diabetes 35.1 25.4 42.3 <0.05
Hypertension 37.4 36.1 38.6 0.142
Fevera) 73.1 71.8 75.0 0.812
Painb) 47.9 47.2 48.0 0.693
Retentionc) 17.4 17.7 17.3 0.541
Voiding symptomsd) 38.6 34.2 44.2 <0.05
Storage symptomse) 64.1 65.2 63.4 0.691
Prior manipulationf) 41.4 21.7 53.8 <0.05
Hematuriag) 54.2 56.2 53.8 0.910
Pyuriah) 77.9 77.3 78.8 0.812
PSA (ng/mL)   20.2±34.1    19.7±33.5    21.3±25.8 0.712
Prostate volume (mL)   37.8±17.3    34.2±17.2    41.6±16.0 <0.05
Values are presented as mean±standard deviation or %.
Group A, recovered without chronic infection; Group B, developed to chronic infection; STI, sexually transmitted infection; PSA, prostate-specific antigen.
a)Body temperature>37.5°C. b)Visual pain score>6. c)Residual urine>300 mL. d)Voiding symptom international prostate symptom score (IPSS) sum>7. 
e)Storage symptom IPSS sum>5. f)Prostate biopsy, catheterization, urodynamic study, transurethral resection of prostate within 4 weeks before onset 
of acute bacterial prostatitis. g)>4 Red blood cells/high power field. h)>4 White blood cells/high power field.




in types or distribution of cultured pathogens (Table 3).
DISCUSSION
The authors implemented this study by separating the clini-
cal prognosis of ABP into those with progression to chronic 
inflammation and those recovered without progression to 
chronic inflammation. The progression rate to chronic inflam-
mation in 437 patients with ABP in total was 11.8%. The rea-
son that authors had included inflammatory CPPS in chronic 
inflammation was because CPPS had multifactor pathological 
bionomics so that inflammation could be its cause. Nickel et 
al. [7] had reported that the triggering factors such as inflam-
mation and dysuria cause inflammation and neurological 
damage to prostate and surrounding fascia, muscle and pelvic 
nerve and repetition of such incidences causes sensitization 
of peripheral tissues and other various phenomena. Patients 
with diabetes has much higher probability for incidence of 
UTI by 5 to 10 times [8]. Although it is presumed that the pres-
ence of urine glucose is related to the increase of prevalence, 
there is nothing scientifically verified, and UTI in patients with 
diabetes is considered as complicated UTI which requires 
treatment with antibiotics for longer period in comparison 
to patients without diabetes. Geerlings [9] had reported that 
patients with diabetes had higher prevalence of other infec-
tions such as asymptomatic bacteriuria and UTI compared to 
patients without diabetes. In this study, also, patients with dia-
betes were progressed from ABP to CI much more than those 
recovered without progression to CI. Given these results, it is 
possible to presume that diabetes has effects on the process of 
progression from ABP to CI and also possible to infer control 
of diabetes has an important role for prevention and treat-
ment of ABP-induced chronic inflammation.
 Prior manipulation such as prostate biopsy, urodynamic 
statistically significant.
RESULTS
Out of 437 patients, 385 patients (88.1%) recovered without 
progression to CI (group A) and 52 patients (11.8%) progressed 
to CI (group B). Among those patients who progressed to CI, 
CBP were 6 patients (1.3%) and inflammatory CPPS were 46 
patients (10.5%).
 The mean ages of each group were 56.0±14.7 years and 
56.8±12.5 years respectively. Fever (71.8% and 75.0%) and py-
uria (77.3% and 78.8%) were the most common clinical symp-
toms in both groups. Alcohol intake (38.5% and 40.4%), diabe-
tes (25.4% and 42.3%), urinary symptoms (34.2% and 44.2%), 
history of prior manipulations (21.7% and 53.8%) and prostate 
size (34.2±17.2 and 41.6±16 mL) were significantly higher in 
group B than in group A, respectively (P<0.05) (Table 1).
 Rates of cystostomy (49.4% and 73.1%), urethral catheter-
ization (9.6% and 53.8%) and antibiotics treatment period 
(36.5±10.6 and 27.5±13.5 days) had shown significant differ-
ences in two groups (P<0.05). During treatment period, the 
antibiotics of cephalosporin and aminoglycoside had been 
used most commonly, and during the treatment period as 
out-patient, quinolone was used most commonly, but there 
was no significant difference between two groups in terms of 
antibiotics types or used period (Table 2).
 The most common bacteria among cultured pathogens was 
Escherichia coli followed by Pseudomonas spp and Klebsiella 
spp. There was no significant difference between two groups 
Table 2. Treatment parameters of acute bacterial prostatitis pa-
tients 
Parameter
Group A  
(n=385)
Group B  
(n=52)
P-value
Not doing cystostomy 49.4 73.1 <0.050
Urethral catheterization   9.6 53.8 <0.050
Duration of antibiotics (day) 36.5±10.6 27.5±13.5 <0.050
Inpatients treatment
   Quinolone 12.7 13.4 0.632
   Cephalosporin+aminoglycoside 58.2 57.6 0.785
   Quinolone+aminoglycoside 17.4 17.3 0.914
   Othersa) 11.7 11.5 0.536
Outpatients treatment
   Cephalosporin 21.8 21.1 0.792
   Quinolone 67.9 67.3 0.902
   Cephalosporin+quinolone 10.9 11.5 0.598
Values are presented as % or mean±standard deviation.
Group A, recovered without chronic infection; Group B, developed to 
chronic infection.
a)Penicillin+aminoglycoside and penicillin+quinolone.








Escherichia coli 61.3 61.5 0.941
Pesudomonas spp 15.1 15.3 0.749
Klebsiella spp 13.4   9.6 0.069
Enterobacter spp   7.5   7.6 0.977
Streptococcus agalaciae   2.7   5.7 0.412
Serratia marcescens 0 0 
CoNS 0 0 
Values are presented as %.
Group A, recovered without chronic infection; Group B, developed to 
chronic infection; CoNS, Coagulase-negative Staphylococci.




study, or urethral catheterization can spread inflammation 
through lymphatic system or blood circulation system. Ha et 
al. [5] had reported that the incidences of prostatic abscess 
as well as chronic prostatitis were significantly higher in the 
group undergone procedures for lower urinary tract system 
before onset of ABP than in the group who did not. In this 
study, the percentage of those with prior history of procedures 
for urinary tract system and who showed progression to CI 
was 53.8%, presenting 2 times higher value than patients re-
covered without progression to CI. In comprehensive view 
of all these details, it is possible to infer that prior procedures 
for urinary tract system have effects on progression from ABP 
to CI thereby reduction of such procedures for lower urinary 
tract system would have an important role in preventing pro-
gression from ABP to CI.
 Most of ABP is assumed as originated by ascending infec-
tion of urinary tract and it is presumed to incur by reflux of 
infected urine into ejaculatory duct or prostatic tube passing 
through posterior urinary tract. The ascending infection of 
urinary tract can also onset by procedures for bladder and uri-
nary tract such as urethral catheterization [10]. Lindert et al. 
[11] had reported urethral catheterization is a causative factor 
of prostatic infection. Meanwhile, as cystostomy can reduce 
the internal pressure of prostatic tube and prevent intrapros-
tatic tube reflux of infected urine, sprapubic cystostomy is be-
ing accepted as the best treatment for ABP. In this study, 53.8 
% of patients with progression to CI had history of urethral 
catheterization and cystostomy was higher percentage in 
patient without progression to CI. So it is possible to infer that 
not doing urethral catheterization or cystostomy may be re-
lated to the progression from ABP to CI. Therefore, restraining 
urethral catheterization and performing cystostomy can be 
helpful for preventing progression to CI in patients with ABP.
 There is a report that many of patients diagnosed with pros-
tatitis were also diagnosed with prostatic hypertrophy [12,13]. 
This condition makes patients more susceptible to inflam-
mation of bladder or prostate as the inflammation either ac-
celerates enlargement of prostate gland itself or such enlarge-
ment induces incomplete urination. Linear mass growth can 
increase intraprostatic tube reflux and internal pressure of 
prostate theoretically. Such conditions elevate bacterial infec-
tion rate of prostate and decrease the treatment rate [14]. In 
this study, the prostatic volume of the group with progression 
to CI was larger than that of the group without progression 
CI. Therefore reduction of prostatic volume can be helpful for 
preventing progression from ABP to CI by reducing voiding 
pressure.
 Approach to the treatment of ABP is determined by the 
clinical symptoms of patient. In most cases, the treatment 
period of ABP in use of antibiotics is 2 weeks at minimum 
and sometimes there are cases requiring 4 to 6 weeks as well 
[15,16]. Fluoroquinolone can be prescribed for 10 days in cas-
es determined as having no accompanying complications and 
even if there is any but determined as minor [17]. Even though 
there had been no agreement on the best treatment method 
so far due to various factors including the needs of consider-
ing antibiotic resistance in specific regions, concomitant use 
of fluoroquinolone and aminoglycoside together in addition 
to inclusion or exclusion of penicillin orthe 2nd and the 3rd 
generation cephalosporin are recommended to the patients 
with ABP being treated as in-patients [18]. When the patient 
is clinically stabilized, has no fever, no urine retention and 
responds as negative to blood and urine culture tests, orally 
taking antibiotics can be initiated for use. In this study, the 
treatment period of in-patients as well as out-patients whose 
ABP had progressed to CI in use of antibiotics was 27.5±13.5 
days whereas the treatment period of patients recovered with-
out progression to CI in use of antibiotics was 36.5±10.6 days. 
In case of in-patients at all ages, the combined therapy of 
cephalosporin and aminoglycoside was used most frequently, 
while in case of out-patients, quinolone was most commonly 
prescribed. 
 The period of antibiotics administration to prevent pro-
gression from acute prostatitis to chronic prostatitis is recom-
mended as two to three weeks administration by Chronic 
Prostatitis Pollaborative Research Network Guidelines and in 
general, it is common to administer for about 1 month [19]. 
In this study, antibiotics had been used in the group with 
progression to chronic inflammation for 27.5±13.5 days and 
in the group without progression to chronic inflammation for 
36.5±10.6 days, presenting sufficient quantity of antibiotics 
had been used in both groups. Of course, the timing to make 
determination on progression to chronic inflammation could 
not be 3 months after always but the authors had implement-
ed this study by designating 3 months after treatment of acute 
prostatitis as the basis of progression or not according to clini-
cal experiences.
 Millan-Rodriguez et al. [20] had reported that gram-nega-
tive bacteria of Enterobacteriaceae group was most commonly 
detected in patients with ABP (87%) and gram-negative bac-
teria among isolated microorganisms was 10%, as reported 
such as Proteus mirabilis, Pseudomonas aeruginosa, Klebsiella, 
Enterococcus spp., and Serratia spp., and Enterococcus spp. 
were detected. In this study, E. coli was detected as the most 
common bacterium that caused ABP.
 In this study, progression rate of CBP and inflammatory 




CPPS was 1.3% and 10.5%, respectively and the progression 
rate of CI was 11.8% from ABP treatment. The patients who de-
veloped to CI were higher in alcohol consumption rate, diabe-
tes, voiding symptoms, prior manuplation rate, enlarged pros-
tate volume, catheterization history rate and short duration of 
antibiotic treatment. Identification of these factors in patients 
with ABP can be helpful for establishing preventive, diagnostic 
and therapeutic strategies against progression to CI. 
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